PKR inhibitor program
Pre-clinical- Indications
- Alzheimer's disease, Mild cognitive impairment, Neurodegenerative diseases
Company intelligence / Profile preview
ProteKt Therapeutics
Ness Ziona, Central District, Israel
- Ownership
- Private
- Employees
- ~25
- Development stage
- Preclinical
01
Overview
ProteKt Therapeutics has discovered multiple novel, potent and selective oral small‑molecule PKR inhibitors, demonstrated in vitro and in vivo proof of concept in models relevant to Alzheimer’s disease and other neurodegenerative indications, and is in lead optimization with a retrospective biomarker clinical study underway; no interventional clinical trials have yet been initiated.[1][4][6][7]
- Therapeutic areas
- OncologyNeurologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bukwang PharmaceuticalFutuRx biotech incubator (Johnson & Johnson Innovation – JJDC, Takeda Ventures, OrbiMed Israel Partners, RMGP, Israel Innovation Authority)
Beyond the preview
Go deeper on ProteKt Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProteKt Therapeutics.